A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) [Oblimersen] Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Docetaxel; Oblimersen
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jul 2008 New trial record.